Issue 1   |  16 February 2021 


Study Overview
The TRACK trial will evaluate whether a small dose of rivaroxaban, a blood-thinning medication, would reduce cardiovascular death or major cardiovascular events in patients with advanced stages of chronic kidney disease.


Meet the Investigators


Progress Updates




Available now...

Background and Rationale video available now;